Article Text

Download PDFPDF

842 High-throughput screening of cancer immunotherapy combinations using a hydrogel-based 3D in vitro tumor platform
  1. Bin Xue1,
  2. Julia Schüler2,
  3. Christopher Harrod1 and
  4. Kolin Hribar1
  1. 1Cypre, Inc., South San Francisco, CA, USA
  2. 2Charles River Laboratories, Freiburg im Breisgau, Germany
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Immunotherapies such as immune checkpoint inhibitors and CAR-T therapies have revolutionized cancer treatment in recent years. However, the success of the immunotherapies has been only limited to a small percentage of patients as primary and secondary resistance to single agent remains common and often results in treatment failure. Combination immunotherapies (e.g. combining multiple immune targets or different therapeutic modalities) have become a potential strategy to combat this drug resistance.

Methods Here we describe a 3D in vitro tumor model platform which can be used for assaying anti-tumor effects of novel immunotherapy combinations. The models incorporate tumor cells derived from patient-derived xenografts, fibroblasts and immune cells in a hydrogel matrix to recreate the complex TME. Tumor size reduction and tumor cell death were determined as endpoint readouts via high content imaging.1 The 96-well high-throughput format allows rapid screening for novel combinations and their additive or synergistic effects across multiple PDX types.

Results As a proof of concept, we tested the combination of anti-CTLA4 (Ipilimumab) and anti-PD1 (Nivolumab), both FDA approved treatments, to showcase their enhancement effect in several PDX models.2 We also observed that dosing kinetics and immune cell density dictated the degree of response for each agent compared to their combination.

Conclusions The Cypre 3D platform is a broadly encompassing tool capable of exploring novel combinations that alter multiple mechanisms of immune response.


  1. Xue B, Schüler J, Harrod CM, Lashuk K, Bomya Z, Hribar KC. A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies. Cells. 2023;12:1–14.

  2. Larkin J, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New Engl J Med. 2019;381:1535–1546.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.